JOIN OUR APAC 2016 STRATEGY MEETING
20th October 2016 | Shangri-la Hotel, Singapore
OUR UNIQUE FORMAT
The Medicinal Chemistry Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Michael EntzerothChief Scientific Officer & Chief Operating Officer
Jun XuDirector, Research Center for Drug Discovery
Sun Yat-Sen University
Zhao-Kui WanHead of Chemistry, Shanghai Discovery Center
Johnson & Johnson
Takeshi YuraVice President
Danio Assay Laboratories
Mahmood AhmedHead, Medicinal Chemistry Unit
Nanyang Technological University
Balasubramanian GopalanCSO & Executive Director
Sakthivel SekarSenior Research Fellow
Biomedical Sciences Institute
WHAT TO EXPECT
Interactive Roundtable Discussions
Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.
Director level one-to-one meetings
We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.
Tailor-fit and Personalized Agenda
Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.
Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.
Thank you for reaching Proventa International
***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.
Our unique strategy meeting platform ensures that delegates can network with peers and benchmark their challenges whilst meeting a select number of supplier organizations that are currently at the forefront of innovation. This in turns helps them to save time and money associated in sourcing the best suppliers to procure solutions in an environment, which is 100% conducive to doing business.
If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAY
Medicinal Chemistry Strategy Meeting APAC 2016,
Very nice generous free floating ideas and a lot of interactions. One to one meeting is also useful particularly for future collaboration it is very fruitful to me to know what they do.
Research Expertise Leader
It is a quicker format to share the general problems encounter and daily work.
Chief Medical Officer
It brought up some really events, actions, emerging technologies, collaborations of different industries. I really enjoy those things.
Senior Research Fellow
Its a quite of unique approach, it is very engaging and they bring bring out what the best of them and make the best contribution.
22 Orange Grove Rd, Singapore 258350
+65 6737 3644
OUR MEDIA PARTNERS
Chief Scientific Officer & Chief Operating Officer, Cennerv Pharma
Director, Research Center for Drug Discovery, Sun Yat-Sen University
Head of Chemistry, Shanghai Discovery Center, Johnson & Johnson
Dr. Zhao-Kui (ZK) Wan, Ph.D.; FRSC
Dr. Wan is currently the Head of Chemistry at Johnson & Johnson’s Shanghai Discovery Center, prior to which he worked at Pfizer for a dozen years. Dr. Wan received his Ph.D. degree from Boston University, and then conducted a postdoctoral research at Harvard University where he discovered the sulfonamidebased asymmetric Nozaki-Hiyama-Kishi reaction. Dr. Wan contributed to the of Eribulin that is now approved for the treatment of breast cancer and sarcoma under the name of Halaven™.
Dr. Wan’s has research experiences in multiple therapeutic areas, including inflammation, immunology, oncology, virology as well as cardiovascular and metabolic diseases. He has made significant contributions to the a number of clinical and preclinical candidates.
Dr. Wan has more than 70 scientific publications in peer-reviewed journals, patents and meeting abstracts. He is an ad hoc reviewer for a number of prestigious scientific journals and serves on the Editorial board for North American Journal of Medicine & Health.
Dr. Wan is a cofounder, a member of Board of Directors of Chinese BioMedical Association (CABA) and served as the President (20092010). He was an Executive Committee member for Sino-American Professionals Association-New England (SA-PANE).
Dr. Wan has won a number of awards, including Young Industrial Investigator in 2008 by the American Chemistry Society, and Fellow of the Royal Society of Chemistry in 2015 by the Royal Society of Chemistry.
Vice President, Jubilant Biosys
Director, Danio Assay Laboratories
Head, Medicinal Chemistry Unit, Nanyang Technological University
Vice President Global Regulatory Affairs, Santen
CSO & Executive Director, Orchid Pharma
Dr.Balasubramanian Gopalan, a Ph.D. in the year 1973 from University of Madras in Synthetic Organic Chemistry and worked as Post Doctoral fellow in Harvard University with Nobel laurite E.J.Corey and then switched over to the industry and joined Syntex Research Inc., California and Bristol-Myers Squibb in New Jersey, USA. He returned to India in the year 1982 and headed drug discovery division of Boots Pharmaceuticals Ltd., Sun Pharma Advanced Research Centre, Glaxo Ltd., Glenmark Research Centre, Matrix Laboratories and finally join as Executive Director and Chief of Orchid Chemicals & Pharmaceuticals in the year 2008. His achievements include discoveries of many new drugs that are in Phase-2 and Phase-3 clinical trial. Many of these discoveries such as Oglemilast (a novel PDE IV inhibitor) was out-licensed to Forest Laboratories, USA for US$190 million over a period of five years & also to Teijin of Japan for US$53 million.
Other of his drug melogliptin a new DPP4 for type 2 diabetes was out-licensed to Merck Germany for US$231 million. He has been a visiting fellow and elected fellow of many academics and universities to his credit he has 50 international patents.
He shares his expertise by training local talents in drug discovery research from Orchid chemical & Pharmaceuticals Ltd., OMR, Chennai.
Senior Research Fellow, Biomedical Sciences Institute